Burrows Scott L 4

What Happened

• Scott L. Burrows, Chief Financial Officer of Spyre Therapeutics (SYRE), exercised 7,500 option shares at $14.50 per share (total cost $108,750) and immediately sold those 7,500 shares in two open-market blocks on July 1, 2026 for aggregate proceeds of $658,039. The sales were reported as 5,775 shares at a weighted average $87.55 (≈ $505,601) and 1,725 shares at a weighted average $88.37 (≈ $152,438). The filing also shows a derivative conversion line (7,500 shares at $0.00) reflecting the exercise/conversion.

Key Details

• Transaction date: July 1, 2026; Form filed July 2, 2026 (timely).
• Option exercise: 7,500 shares exercised at $14.50 (cost $108,750).
• Sales: 5,775 shares at weighted avg $87.55 (range $87.13–$88.05); 1,725 shares at weighted avg $88.37 (range $88.17–$89.01). Total proceeds ≈ $658,039.
• Shares owned after transaction: Not specified in the filing.
• Footnotes: Sales executed pursuant to a Rule 10b5-1 trading plan adopted Nov 10, 2025 (F1). Price rows are weighted averages; the filer will provide per-price breakdowns on request (F2, F3). Filing also discloses existing RSUs (67,476) and option grant details/vesting (F4, F5).
• Filing timeliness: No late filing indicated.

Context

• This was an exercise followed by immediate sale of the resulting shares (effectively a cashless exercise / sale of all exercised shares). The presence of a 10b5-1 plan indicates the sales were pre-arranged. The filing includes background on outstanding options and RSUs (vesting schedules) but does not state Burrows’ post-transaction holdings; contact the company or review the full Form 4 for complete ownership details.